NTRB NutriBand Inc.
Orthopedic, Prosthetic & Surgical Appliances & Supplies · Nasdaq · SEC CIK 1676047 · Fiscal year ends 01/31
Financial factors as of 2026-07-31 (2027Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY-37.3%
TTM net income YoY32.2%
TTM EPS YoY83.0%
Revenue 3-yr CAGR-10.8%
Net income 3-yr CAGR—
Margins
Gross margin33.1%
Operating margin-435.6%
Net margin-430.4%
FCF margin—
EBITDA margin-426.5%
Returns
ROE-100.7%
ROA-84.6%
ROIC (approx.)-326.9%
Asset turnover0.20x
Leverage & solvency
Liabilities / assets15.3%
Debt / equity0.00x
Current ratio4.21x
Interest coverage-339.35x
Cash quality & payout
Operating cash flow / net income0.52x
Accruals ratio-40.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-01-31 | FY20252025-01-31 |
|---|---|---|
| Income statement | ||
| Revenue | $2.04M | $2.14M |
| Cost of revenue | $1.47M | $1.40M |
| Gross profit | $566,308 | $743,317 |
| R&D expense | $1.89M | $3.12M |
| SG&A expense | $6.99M | $4.31M |
| Operating income | -$8.32M | -$10.28M |
| Interest expense | $22,535 | $21,407 |
| Pretax income | -$8.23M | -$10.48M |
| Net income | -$8.23M | -$10.48M |
| EBITDA | -$8.12M | -$10.00M |
| EPS (basic) | -2.58 | -0.99 |
| EPS (diluted) | -2.58 | -0.99 |
| Weighted avg. shares (diluted) | 11.64M | 10.61M |
| Balance sheet | ||
| Cash & equivalents | $4.57M | $4.31M |
| Receivables | $118,404 | $73,847 |
| Inventory | $117,987 | $212,041 |
| Current assets | $4.99M | $4.79M |
| PP&E, net | $567,255 | $695,063 |
| Goodwill | $1.72M | $1.72M |
| Intangibles | $200,427 | $261,092 |
| Total assets | $7.55M | $7.47M |
| Current liabilities | $784,281 | $982,845 |
| Total liabilities | $868,447 | $1.04M |
| Shareholders' equity | $6.68M | $6.43M |
| Shares outstanding | 12.16M | 11.07M |
| Cash flow statement | ||
| Operating cash flow | -$5.13M | -$4.63M |
| Capital expenditure | $5,324 | $92,043 |
| Free cash flow | -$5.14M | -$4.72M |
| Investing cash flow | -$5,324 | -$92,043 |
| Financing cash flow | $5.40M | $8.54M |
| Depreciation & amortization | $193,797 | $285,054 |
| Stock-based compensation | $2.63M | $1.41M |
Free plan shows the latest 2 periods; Pro shows all 10 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.